1. Home
  2. SLBT vs ANNX Comparison

SLBT vs ANNX Comparison

Compare SLBT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SL Science Holding Limited Ordinary Shares

SLBT

SL Science Holding Limited Ordinary Shares

HOLD

Current Price

$1.35

Market Cap

644.9M

Sector

N/A

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$3.70

Market Cap

726.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLBT
ANNX
Founded
N/A
2011
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
644.9M
726.1M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
SLBT
ANNX
Price
$1.35
$3.70
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
56.9K
★ 3.4M
Earning Date
N/A
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$2.54
52 Week High
$6.25
$7.18

Technical Indicators

Market Signals
Indicator
SLBT
ANNX
Relative Strength Index (RSI) 24.71 41.32
Support Level N/A $3.36
Resistance Level $1.75 $4.37
Average True Range (ATR) 0.13 0.24
MACD 0.00 0.02
Stochastic Oscillator 27.40 40.85

Price Performance

Historical Comparison
SLBT
ANNX

About SLBT SL Science Holding Limited Ordinary Shares

SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: